Background Renal transplant patients receiving combined immunosuppressive agents showed markedly low rates of in-stent restenosis and MACE after coronary revascularization with BMS. The use of DES has reduced the rates of clinical and angiographic restenosis. The occurrence of late or very late stent thrombosis among DES treated patients has been described. The purpose of this study was to assess the role of DES in renal transplant patients who underwent percutaneous coronary stenting. Methods and Results We included 33 renal transplant patients with 45 coronary lesions underwent coronary stenting using BMS (BMS group) and 26 renal transplant patients with 44 lesions underwent coronary stenting using DES (DES group). The primary end point was incidence of angiographic binary restenosis and late loss. The secondary end point was incidence of major adverse cardiovascular events. The baseline clinical and angiographical characteristics were similar. In BMS group, the cyclosporine blood level at the time of procedure was 192.5짹68 mg/day and 147.4짹65.3 mg/day in DES group (p=0.732). The rate of ISR was 7.1% in BMS group and 9.4% in DES group (p=0.755). The mean late loss was 0.47짹0.57 mm in BMS group compared to 0.29짹0.70 mm in DES group (p=0.330). The overall rate of MACE was 6.1% in renal transplant group and 7.7% in DES group (p=0.805). Conclusions Although DES insignificantly reduced late loss compared with BMS, the rates of ISR and MACE were not different between two groups. Renal transplant patients should be considered a low-risk group, with low ISR and MACE.